Stereotaxis to Report Fourth Quarter and Full Year 2013 Financial Results on
February 25, 2014
ST. LOUIS, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
today announced that it will release financial results for its 2013 fourth
quarter and full year ended December 31, 2013 on Tuesday, February 25, 2014
after the close of the U.S. financial markets. The Company will host a
conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the
Company's results and corporate developments.
What: Stereotaxis fourth quarter and full year 2013 financial
results conference call
When: Tuesday, February 25^th at 4:30 p.m. Eastern Time (1:30 p.m.
Dial In Number: 877-941-1427 (US and Canada)
Webcast: To access the live and replay webcast, please visit the
investor relations section of Stereotaxis'
website at www.stereotaxis.com
Call Replay: A replay of the call will be available approximately one hour
following the end of the call
through 11:59 p.m. ET on Tuesday, March 4, 2014.
Replay Numbers: 800-406-7325 (US and Canada)
Replay passcode: 4670284#
Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core Epoch™
Solution includes the Niobe® ES Remote Magnetic Navigation system, the
Odyssey® portfolio of lab optimization, networking and patient information
management systems and the Vdrive™ Robotic Mechanical Navigation system and
The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Sono™ ICE catheter
manipulator has received U.S. clearance, and the V-Loop™ circular catheter
manipulator will soon be submitted for review by the U.S. Food and Drug
Administration. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability to
raise additional capital on a timely basis and on terms that are acceptable,
its ability to continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend, repay or
refinance indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global economic
conditions on the ability and willingness of customers to purchase its systems
and the timing of such purchases, the outcome of various shareholder
litigation filed against Stereotaxis, competitive factors, changes resulting
from the recently enacted healthcare reform in the U.S., including changes in
government reimbursement procedures, dependence upon third-party vendors,
timing of regulatory approvals, and other risks discussed in the Company's
periodic and other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no obligation
to update these statements for revisions or changes after the date of this
release. There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any particular period
or at all because some of these purchase orders and other commitments are
subject to contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified, delayed or
canceled, either by their express terms, as a result of negotiations, or by
overall project changes or delays.
CONTACT: Company Contact:
Chief Financial Officer
Todd Kehrli / Jim Byers
MKR Group, Inc.
Press spacebar to pause and continue. Press esc to stop.